BioVaxys and Sona Nanotech Enter Research Collaboration

About this update from Sona Nanotech, Inc.

[{"type":"text","content":"Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary biocompatible Gold Nanorod ("GNR") technology which elicits a strong immune response.","length":839,"tagName":"p"},{"type":"text","content":"Carman Giacomantonio, MD, Chief Medical Officer ("CMO") for Sona Nanotech Inc., commented, "Looking beyond our approaching first-in-human Early Feasibility Study clinical trial for our THT cancer therapy, Sona continues to conduct research to build our pipeline of programs to fully exploit the potential of our GNR technology platform. To that end, we're pleased to enter this research collaboration with BioVaxys whose DPX technology provides a unique delivery system that better presents antigens to the immune system. We believe that DPX, with its immune stimulating properties and antigen presentation capabilities, could be an ideal carrier for the neo-antigens that Sona's THT enables, thereby accelerating THT's efficacy. We look forward to working with the BioVaxys team to quickly assess the potential for technology synergies." ","length":870,"tagName":"p"},{"type":"text","content":""We are very pleased to have the opportunity to evaluate synergies between our DPX platform and Sona's THT and GNR technologies, as our collaboration is ideal for advancing the highly promising applications of our respective technologies," says Kenneth Kovan, President and Chief Operating Officer at BioVaxys. "With Sona's exciting study data and the clinical trial data we have with DPX it's conceivable that our collaboration could lead to a new and even better treatment for immunotherapy-resistant solid tumors.&quot...

More updates from Sona Nanotech, Inc.